Barbara Herkert

Biochemistry, Genetics and Molecular Biology · Life Sciences

10h-index572citations50works0.02yr avg
OpenAlex↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Melanoma and MAPK Pathways(25), PI3K/AKT/mTOR signaling in cancer(21), Synthesis and biological activity(10), Synthesis of Tetrazole Derivatives(6), Advanced Chemical Physics Studies(3)

Publications50 total

Supplementary Table 1 from Maximizing the Efficacy of MAPK-Targeted Treatment in <i>PTEN</i><sup>LOF</sup><i>/BRAF</i><sup>MUT</sup> Melanoma through PI3K and IGF1R Inhibition
2023Open Access
Supplementary Figure 5 from Maximizing the Efficacy of MAPK-Targeted Treatment in <i>PTEN</i><sup>LOF</sup><i>/BRAF</i><sup>MUT</sup> Melanoma through PI3K and IGF1R Inhibition
2023Open Access
Supplementary Figure 4 from Maximizing the Efficacy of MAPK-Targeted Treatment in <i>PTEN</i><sup>LOF</sup><i>/BRAF</i><sup>MUT</sup> Melanoma through PI3K and IGF1R Inhibition
2023Open Access
Supplementary Figure Legends from Maximizing the Efficacy of MAPK-Targeted Treatment in <i>PTEN</i><sup>LOF</sup><i>/BRAF</i><sup>MUT</sup> Melanoma through PI3K and IGF1R Inhibition
2023Open Access
Supplementary Figure 6 from Maximizing the Efficacy of MAPK-Targeted Treatment in <i>PTEN</i><sup>LOF</sup><i>/BRAF</i><sup>MUT</sup> Melanoma through PI3K and IGF1R Inhibition
2023Open Access
Supplementary Figure 2 from Maximizing the Efficacy of MAPK-Targeted Treatment in <i>PTEN</i><sup>LOF</sup><i>/BRAF</i><sup>MUT</sup> Melanoma through PI3K and IGF1R Inhibition
2023Open Access
Supplementary Table 2 from Maximizing the Efficacy of MAPK-Targeted Treatment in <i>PTEN</i><sup>LOF</sup><i>/BRAF</i><sup>MUT</sup> Melanoma through PI3K and IGF1R Inhibition
2023Open Access
Supplementary Figure 8 from Maximizing the Efficacy of MAPK-Targeted Treatment in <i>PTEN</i><sup>LOF</sup><i>/BRAF</i><sup>MUT</sup> Melanoma through PI3K and IGF1R Inhibition
2023Open Access
Supplementary Figure 3 from Maximizing the Efficacy of MAPK-Targeted Treatment in <i>PTEN</i><sup>LOF</sup><i>/BRAF</i><sup>MUT</sup> Melanoma through PI3K and IGF1R Inhibition
2023Open Access
Supplementary Figure Legends from Maximizing the Efficacy of MAPK-Targeted Treatment in <i>PTEN</i><sup>LOF</sup><i>/BRAF</i><sup>MUT</sup> Melanoma through PI3K and IGF1R Inhibition
2023Open Access
Supplementary Table 2 from Maximizing the Efficacy of MAPK-Targeted Treatment in <i>PTEN</i><sup>LOF</sup><i>/BRAF</i><sup>MUT</sup> Melanoma through PI3K and IGF1R Inhibition
2023Open Access
Supplementary Figure 7 from Maximizing the Efficacy of MAPK-Targeted Treatment in <i>PTEN</i><sup>LOF</sup><i>/BRAF</i><sup>MUT</sup> Melanoma through PI3K and IGF1R Inhibition
2023Open Access
Supplementary Figure 4 from Maximizing the Efficacy of MAPK-Targeted Treatment in <i>PTEN</i><sup>LOF</sup><i>/BRAF</i><sup>MUT</sup> Melanoma through PI3K and IGF1R Inhibition
2023Open Access
Supplementary Materials and Methods from Maximizing the Efficacy of MAPK-Targeted Treatment in <i>PTEN</i><sup>LOF</sup><i>/BRAF</i><sup>MUT</sup> Melanoma through PI3K and IGF1R Inhibition
2023Open Access
Data from Maximizing the Efficacy of MAPK-Targeted Treatment in <i>PTEN</i><sup>LOF</sup><i>/BRAF</i><sup>MUT</sup> Melanoma through PI3K and IGF1R Inhibition
2023Open Access
Data from Maximizing the Efficacy of MAPK-Targeted Treatment in <i>PTEN</i><sup>LOF</sup><i>/BRAF</i><sup>MUT</sup> Melanoma through PI3K and IGF1R Inhibition
2023Open Access
Supplementary Figure 5 from Maximizing the Efficacy of MAPK-Targeted Treatment in <i>PTEN</i><sup>LOF</sup><i>/BRAF</i><sup>MUT</sup> Melanoma through PI3K and IGF1R Inhibition
2023Open Access
Supplementary Figure 9 from Maximizing the Efficacy of MAPK-Targeted Treatment in <i>PTEN</i><sup>LOF</sup><i>/BRAF</i><sup>MUT</sup> Melanoma through PI3K and IGF1R Inhibition
2023Open Access
Supplementary Figure 2 from Maximizing the Efficacy of MAPK-Targeted Treatment in <i>PTEN</i><sup>LOF</sup><i>/BRAF</i><sup>MUT</sup> Melanoma through PI3K and IGF1R Inhibition
2023Open Access
Supplementary Figure 9 from Maximizing the Efficacy of MAPK-Targeted Treatment in <i>PTEN</i><sup>LOF</sup><i>/BRAF</i><sup>MUT</sup> Melanoma through PI3K and IGF1R Inhibition
2023Open Access
page 1 of 3Next →

Frequent Co-authors

Audrey Kauffmann(29), Sandra Mollé(29), Christian Schnell(29), Thomas Ferrat(29), Hans Voshol(29), Janina Juengert(29), Grégory Marszalek(29), Malika Kazic-Legueux(29), Éric Billy(29), David A. Ruddy(29), Mark Stump(29), Daniel Guthy(29), Mitko Ristov(29), Sauveur-Michel Maira(29), William R. Sellers(29), Francesco Hofmann(29), Michael N. Hall(29), Saskia M. Brachmann(29), Hélène Erasimus(28), Keith Calkins(28)